Biomedical Research

Objective: To observe the therapeutic effect of simvastatin combined with vein infusion of hyperoxic fluid on the cardiac function, respiratory mechanics and airway inflammation factor of patients with Chronic Obstructive Pulmonary Disease (COPD) combined with Coronary Heart Disease (CHD).

Method: 96 patients with COPD combined with CHD who accorded with diagnostic criteria were randomly divided into observation group and control group, each containing 48 patients. The control group was given with vein infusion of hyperoxic fluid, while the observation group was given with simvastatin combined with vein infusion of hyperoxic fluid. The index change of two groups before treatment and 5 d after treatment were compared, including cardiac function (LVEF-Left Ventricular Ejection Fraction and LVDD-Left Ventricular End Diastolic Dimension), blood fat (TC-Total Cholesterol, LDL-Low Density Lipoprotein), oxygenation index (PaO2/FiO2), respiratory mechanical indexes (lung compliance, PIP-peak inspiratory pressure, airway platform pressure, airway resistance), phlegm supernate inflammation factors (IL-8, TNF-α, Neu/Leu%).

Results: 5 d after treatment, LVEF of both groups were increased in different degrees, while LVDD, TC and LDL-C of both groups were decreased (P<0.05). After treatment, the LVEF of observation group was significantly higher than that of control group; TC and LDL-C of observation group were significantly lower than that of control group, and the intergroup difference was of statistical significance (P<0.05); PaO2/FiO2, Cst, Cdyn of observation group were improved more quickly than control group (P<0.05); the PIP, Pplat and RE of observation group were improved more quickly compared with control group(P<0.05); the IL-8, TNF-α and Neu/Leu% of observation group were also improved more quickly compared with control group(P<0.05).

Conclusion: The combined therapy of simvastatin and vein infusion of hyperoxic fluid can effectively improve the cardiac function, blood lipid level, respiratory mechanics of patients with COPD plus CHD, and effectively reduce level of airway inflammation factors. This combined therapy is an ideal method to treat COPD plus CHD, which should be promoted in clinics.

Author(s): Xiao-Shan Zhang, Sha-Ning Yang, Yu-Jing Wang, Xue-xin Yang, Li-Jun Jin, Zhong-Quan Zhou
Abstract | Full-Text | PDF

Share this